83 Citations (Scopus)

Abstract

A broad range of nanomedicines is being developed to improve drug delivery for CNS disorder. The structure of the blood-brain barrier (BBB), the presence of efflux pumps and the expression of metabolic enzymes pose hurdles for drug-brain entry. Nanoformulations can circumvent the BBB to improve CNS-directed drug delivery by affecting such pumps and enzymes. Alternatively, they can be optimized to affect their size, shape, and protein and tipid coatings to facilitate drug uptake, release and ingress across the barrier. This is important as the brain is a sanctuary for a broad range of pathogens including HIV-1. Improved drug delivery to the CNS would affect pharmacokinetic and drug biodistribution properties. This article focuses on how nanotechnology can serve to improve the delivery of antiretroviral medicines, termed nanoART, across the BBB and affect the biodistribution and clinical benefit for HIV-1 disease.

Original languageEnglish (US)
Pages (from-to)557-574
Number of pages18
JournalNanomedicine
Volume4
Issue number5
DOIs
StatePublished - Aug 12 2009

Fingerprint

Drug delivery
drug
brain
Blood-Brain Barrier
Brain
Enzymes
Pumps
Pharmaceutical Preparations
Medical nanotechnology
Pharmacokinetics
blood
Pathogens
HIV-1
human immunodeficiency virus
Nanotechnology
Medicine
pump
Nanomedicine
Membrane Transport Proteins
enzyme

Keywords

  • BBB
  • CNS
  • Drug delivery
  • HIV
  • Nanoparticles
  • Nanotechnology

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Materials Science(all)

Cite this

NanoART, neuroAIDS and CNS drug delivery. / Nowacek, Ari; Gendelman, Howard Eliot.

In: Nanomedicine, Vol. 4, No. 5, 12.08.2009, p. 557-574.

Research output: Contribution to journalReview article

Nowacek, Ari ; Gendelman, Howard Eliot. / NanoART, neuroAIDS and CNS drug delivery. In: Nanomedicine. 2009 ; Vol. 4, No. 5. pp. 557-574.
@article{a74ca579570b462593a1237596429c06,
title = "NanoART, neuroAIDS and CNS drug delivery",
abstract = "A broad range of nanomedicines is being developed to improve drug delivery for CNS disorder. The structure of the blood-brain barrier (BBB), the presence of efflux pumps and the expression of metabolic enzymes pose hurdles for drug-brain entry. Nanoformulations can circumvent the BBB to improve CNS-directed drug delivery by affecting such pumps and enzymes. Alternatively, they can be optimized to affect their size, shape, and protein and tipid coatings to facilitate drug uptake, release and ingress across the barrier. This is important as the brain is a sanctuary for a broad range of pathogens including HIV-1. Improved drug delivery to the CNS would affect pharmacokinetic and drug biodistribution properties. This article focuses on how nanotechnology can serve to improve the delivery of antiretroviral medicines, termed nanoART, across the BBB and affect the biodistribution and clinical benefit for HIV-1 disease.",
keywords = "BBB, CNS, Drug delivery, HIV, Nanoparticles, Nanotechnology",
author = "Ari Nowacek and Gendelman, {Howard Eliot}",
year = "2009",
month = "8",
day = "12",
doi = "10.2217/nnm.09.38",
language = "English (US)",
volume = "4",
pages = "557--574",
journal = "Nanomedicine",
issn = "1743-5889",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - NanoART, neuroAIDS and CNS drug delivery

AU - Nowacek, Ari

AU - Gendelman, Howard Eliot

PY - 2009/8/12

Y1 - 2009/8/12

N2 - A broad range of nanomedicines is being developed to improve drug delivery for CNS disorder. The structure of the blood-brain barrier (BBB), the presence of efflux pumps and the expression of metabolic enzymes pose hurdles for drug-brain entry. Nanoformulations can circumvent the BBB to improve CNS-directed drug delivery by affecting such pumps and enzymes. Alternatively, they can be optimized to affect their size, shape, and protein and tipid coatings to facilitate drug uptake, release and ingress across the barrier. This is important as the brain is a sanctuary for a broad range of pathogens including HIV-1. Improved drug delivery to the CNS would affect pharmacokinetic and drug biodistribution properties. This article focuses on how nanotechnology can serve to improve the delivery of antiretroviral medicines, termed nanoART, across the BBB and affect the biodistribution and clinical benefit for HIV-1 disease.

AB - A broad range of nanomedicines is being developed to improve drug delivery for CNS disorder. The structure of the blood-brain barrier (BBB), the presence of efflux pumps and the expression of metabolic enzymes pose hurdles for drug-brain entry. Nanoformulations can circumvent the BBB to improve CNS-directed drug delivery by affecting such pumps and enzymes. Alternatively, they can be optimized to affect their size, shape, and protein and tipid coatings to facilitate drug uptake, release and ingress across the barrier. This is important as the brain is a sanctuary for a broad range of pathogens including HIV-1. Improved drug delivery to the CNS would affect pharmacokinetic and drug biodistribution properties. This article focuses on how nanotechnology can serve to improve the delivery of antiretroviral medicines, termed nanoART, across the BBB and affect the biodistribution and clinical benefit for HIV-1 disease.

KW - BBB

KW - CNS

KW - Drug delivery

KW - HIV

KW - Nanoparticles

KW - Nanotechnology

UR - http://www.scopus.com/inward/record.url?scp=68249144974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68249144974&partnerID=8YFLogxK

U2 - 10.2217/nnm.09.38

DO - 10.2217/nnm.09.38

M3 - Review article

C2 - 19572821

AN - SCOPUS:68249144974

VL - 4

SP - 557

EP - 574

JO - Nanomedicine

JF - Nanomedicine

SN - 1743-5889

IS - 5

ER -